Global Antipsychotic Drugs Market, By Therapeutic Class (First Generation, Second Generation, and Third Generation), By Disease (Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia, and Other Diseases), By Distribution Channel (Hospital Pharmacies, Drug Stores, and Online Pharmacies), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032

Report Overview

The Global Antipsychotic Drugs Market size was valued at USD 17 Billion in 2022 and is expected to grow to USD 29.5 Billion in 2032. Between 2023 and 2032, this market is estimated to register a CAGR of 5.8%.

The category of mental diseases is one of the disease groups that is anticipated to have significant growth in patients globally in the current healthcare environment. Psychosis is a significant sign of mental disease, because, in this, the patient is unable to absorb information, due to the individual’s loss of life reality.

The increased prevalence of schizophrenia and bipolar disorder is too accountable for the rapidly increasing demand for these drugs. The market is growing as a result of an increase in the geriatric population, an increase in the prevalence of mental diseases, and an increase in programs to raise general awareness of mental health. The demand for antipsychotic medications is also growing as a result of increased information about mental illnesses and campaigning for them to be treated with more respect and with less stigma.

*Actual Numbers Might Vary In The Final Report

Key Takeaways

• The global antipsychotic drugs market was valued at USD 17 billion in 2022.
• The market is projected to grow to USD 29.5 billion by 2032.
• The market is estimated to register a CAGR of 5.8% between 2023 and 2032.
• By Therapeutic Class, in 2022, the second-generation segment dominated the Antipsychotic Drugs market.
• In the Disease analysis, schizophrenia accounted for the largest market share in 2022.
• By Distribution Channel in 2022, the hospital pharmacies segment had the largest market share.
• In 2022, North America held the highest revenue share of 45% in the market.
• The APAC region is expected to experience the highest CAGR among all regions.

Driving Factors

The healthcare system, services, and its providers are under added stress due to the increase of people suffering from serious mental diseases. The government’s attention is now on creating a high and reliable level of knowledge of diseases and associated symptoms. As a result, the market’s key players are investing and devoting their best resources to developing highly efficient and secure drugs that can be applied to treat people with psychotic diseases in all countries.

The need for face-to-face mental health care, particularly among the elderly, has decreased due to fear of disease. A number of services have also been forced to shift to remote healthcare, with varying degrees of success, offering consultations over the phone or on web platforms.

Physicians can use telemedicine to deliver efficient over-the-counter treatments and provide guidelines on dispensing prescription and non-prescription medications. Moreover, many patients are anxious about going to the pharmacy to pick up medications.

Restraining Factors

One of the main factors expected to prevent market players from expanding globally during the forecast period is a lack of knowledge and recognition. Most individuals are unaware of the fact that psychotic disorders are becoming more prevalent in the world. In addition, even those in the target audience who have a thorough awareness of the sickness are unaware of the medicines and therapies that can benefit those who are affected.

Growth Opportunities

The development of the market is being driven by improvements in medical technology and an environment with greater competition. Government funding will rise, and businesses will increase their R&D efforts, opening up new income prospects that will fuel market expansion. The government is putting a lot of effort into raising public knowledge about diseases and the effectiveness of the medicines taken to treat them.

Treating patients suffering from psychotic disorders globally has led to significant demand for highly effective and safe medicines. In addition, the companies are concentrating on releasing attempts to cut injectable antipsychotic medications that help to deal with the requirement to monitor the patient’s drug consumption.

The expansion of the worldwide market for antipsychotic drugs is predicted to be supported by this in the upcoming years. As a result, there is a considerable need for efficient psychiatric disorder treatment. Hence, a large number of pharmaceutical companies have introduced long-acting injectable antipsychotic medications.

Due to the advantages associated with these long-acting injectables, these medications are now being used more often, which is driving market expansion.

Trending Factors

Antipsychotic drug research and development has changed as customers are becoming more conscious of the cost burden. As a result, there is a considerable need for efficient psychiatric disorder treatment. Hence, a large number of pharmaceutical companies have introduced long-acting injectable antipsychotic medications. Due to the advantages associated with these long-acting injectables, these medications are now being used more often, which is driving market expansion.

Schizophrenia is a severe mental illness in which the sufferer experiences aberrant thinking, acting feeling, and self-awareness. If this illness is not appropriately managed, the risk of mortality may grow. As a result, numerous businesses are concentrating on creating new drugs to treat this illness. Chlorpromazine, Olanzapine, Aripiprazole, and other treatments licensed each year are just a few examples of the several FDA-approved medications, now available on the market that are expected to spur market expansion over the duration of the forecast period.

Addiction and serious consequences often result from the overprescription of these medications. People from wealthy nations like North America are affected by this illness. Governmental restrictions on these drugs limited the market’s expansion. The companies are concentrating on the creation of new injectable antipsychotic medications that will help to deal with the need for patients to be tracked for drug use. The global market for antipsychotic medications is anticipated to develop as a result of these factors.

Therapeutic Class Analysis

The Second Generation Segment is the Most Lucrative Segment in the Therapeutic Class Analysis

Market segments include first-generation, second-generation, and third-generation based on the therapeutic class. Second generation dominated the global market during the expected period of time. The overwhelming presence of second-generation pharmaceuticals on the global market is responsible for this market segment’s domination. SEROQUEL XR, ZYPREXA, HAFYERA, and INVEGA are a few of the well-known second-generation antipsychotics.

Also, the improved efficacy and enhanced safety of the medications from this generation will aid in the expansion of this market. Due to the relatively lower safety profile of these medications, the first-generation segment is predicted to increase at the slowest CAGR. The sector of third-generation is predicted to have the highest CAGR during the forecast period. New product launches in this market and a higher level of technological excellence compared to other medicine classes are some factors that have contributed to the segment’s high growth.

Disease Analysis

The Schizophrenia Segment Accounted for the Largest Revenue Share in Antipsychotic Drugs Market

The global market is divided into segments based on disease, including dementia, bipolar disorder, schizophrenia, and others. Due to the high prevalence of this disease worldwide and the numerous product launches in this market, the category of schizophrenia is anticipated to expand at the highest rate during the forecast period. Widespread use of these medications to stabilize the disease’s symptoms, the bipolar disorder market is anticipated to hold the second-largest market share.

Due to the use of well-known antipsychotic medications like Rexulti, the unipolar depression category is expected to hold the third biggest market share. Throughout the projected period, it is anticipated that the dementia segment’s market share would decrease.

Distribution Channel Analysis

The hospital pharmacies segment is anticipated to hold the largest market share

The market is divided into hospital pharmacies, drug stores, and online pharmacies based on the distribution channel. During the forecast period, the hospital pharmacies segment is anticipated to hold the largest market share. This segment’s dominance can be attributed to the fact that the majority of treatment medications can only be prescribed following thorough examinations by qualified medical professionals at these institutions.

The second-largest market share is anticipated to go to the drug stores sector. Refills on prescriptions can be obtained in these places, which are regarded as a significant distribution channel for oral prescription medications. Because they promote patient convenience and ease when it comes to purchasing medications, internet pharmacies are predicted to have the highest CAGR during the projected period.

Key Market Segments

Based on Therapeutic Class

• First Generation
• Second Generation
• Third Generation

Based on Disease

• Schizophrenia
• Bipolar Disorder
• Unipolar Depression
• Dementia
• Other Diseases

Based on the Distribution Channel

• Hospital Pharmacies
• Drug Stores
• Online Pharmacies

Regional Analysis

Over the forecast period, North America is anticipated to dominate the market.

Due to its well-established healthcare infrastructure, superior regulatory environment, rising prevalence of mental diseases, and government backing in the nations of this area, North America is predicted to dominate the market share. The main element fueling market expansion in the area is the rising prevalence of schizophrenia and mental disease in the population.

For instance, it has been noted that around 1% of the American population suffers from schizophrenia, according to information published by John Hopkins Medicine in 2020 under the title “Mental Health Disorder Statistics”.

According to projections of the market share for antipsychotic drugs, Europe is the second-most important area. The great prevalence of mental problems in the area and the growing awareness of psychiatric illnesses are to account for this. Particularly in rising nations like India and China, the market in the Asia-Pacific is predicted to expand at the fastest rate.

Key Regions

• North America
  • The US
  • Canada
  • Mexico
• Western Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Portugal
  • Ireland
  • Austria
  • Switzerland
  • Benelux
  • Nordic
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • The Czech Republic
  • Greece
  • Rest of Eastern Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Australia & New Zealand
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Colombia
  • Chile
  • Argentina
  • Costa Rica
  • Rest of Latin America
• Middle East & Africa
  • Algeria
  • Egypt
  • Israel
  • Kuwait
  • Nigeria
  • Saudi Arabia
  • South Africa
  • Turkey
  • United Arab Emirates
  • Rest of MEA

Key Players Analysis

Antipsychotic drug markets are moderately competitive and include both national and international competitors. Global competitors now control a sizable portion of the market because the US FDA has approved the majority of the medications used to treat the disease.

It is anticipated that small firms will control a sizeable portion of the market in the future due to their increased focus on market penetration. AbbVie Inc., Pfizer Inc., Otsuka Pharmaceutical Co. Ltd., GlaxoSmithKline plc, Eli Lily and Company, and Johnson & Johnson, are the major market participants.

 Market Key Players

• Drive DeVilbissSidhil Ltd.
• ALPS Mountaineering
• Sumitomo Dainippon Pharma Co. Ltd.
• Abbvie Inc
• Alkermes Plc
• AstraZeneca Plc
• Reddy’s Laboratories Ltd
• Eli Lilly and Company
• Johnson and Johnson
• Otsuka Holdings Co. Ltd
• Teva Pharmaceutical Industries Ltd
• Bristol-Myers Squibb Company
• Other Key Players

Recent Developments

• Alkermes plc released encouraging results from ENLIGHTEN-early, a phase 3b research that evaluated the effectiveness of LYBALVI in the treatment of schizophrenia disorder, in February 2022.
• According to a January 2022 announcement from Otsuka Pharmaceutical Co.Ltd., Otsuka American Pharmaceutical Inc., and Lundbeck, Inc., the US Food and Drug Administration has accepted REXULTI’s supplemental new drug application for the treatment of schizophrenia in patients aged 13 to 17.

Report Scope